Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b dose-finding study of 177Lu-NeoB with radiotherapy and temozolomide in newly diagnosed glioblastoma and as monotherapy in recurrent glioblastoma
MOH_2024-01-14_013184Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Jan 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of neobomb1 in glioblastoma (GBM) (2 arms), sponsored by Novartis. Primary endpoint: Safety and dose-finding. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
neobomb1
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on MOH_2024-01-14_013184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-14_013184.